Literature DB >> 9182238

Comparative effects of the GABA uptake inhibitors, tiagabine and NNC-711, on extracellular GABA levels in the rat ventrolateral thalamus.

D A Richards1, N G Bowery.   

Abstract

The primary mechanism by which the action of synaptically released GABA is thought to be terminated is by re-uptake into neurones and glial cells, and the pharmacological inhibition of this uptake may be beneficial in conditions where decreased GABAergic transmission has been implicated, such as epilepsy. We have compared the effects of two of these uptake inhibitors, tiagabine and NNC-711, on extracellular GABA levels in the thalamus of the rat, after both systemic and local administration. Both compounds produced dose-dependent increases in GABA concentration irrespective of the route of administration, but the concentrations required to produce increased extracellular GABA levels were considerably higher than those known to be effective for anticonvulsant purposes. These data suggest that, initially at least, alternative GABA transporters, not susceptible to inhibition by the compounds used, may still be able to remove synaptically released GABA from the extracellular space.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9182238     DOI: 10.1007/BF02529130

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  20 in total

1.  Inhibition of GABA uptake in rat brain slices by nipecotic acid, various isoxazoles and related compounds.

Authors:  P Krogsgaard-Larsen; G A Johnston
Journal:  J Neurochem       Date:  1975-12       Impact factor: 5.372

2.  Uptake and release of nipecotic acid by rat brain slices.

Authors:  G A Johnston; A L Stephanson; B Twitchin
Journal:  J Neurochem       Date:  1976-01       Impact factor: 5.372

3.  Kinetic characterization of inhibition of gamma-aminobutyric acid uptake into cultured neurons and astrocytes by 4,4-diphenyl-3-butenyl derivatives of nipecotic acid and guvacine.

Authors:  O M Larsson; E Falch; P Krogsgaard-Larsen; A Schousboe
Journal:  J Neurochem       Date:  1988-03       Impact factor: 5.372

4.  Weak effects of local and systemic administration of the GABA uptake inhibitor, SK&F 89976, on extracellular GABA in the rat striatum.

Authors:  P C Waldmeier; K Stöcklin; J J Feldtrauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

5.  Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine.

Authors:  N Y Walton; S Gunawan; D M Treiman
Journal:  Epilepsy Res       Date:  1994-12       Impact factor: 3.045

6.  Lack of tolerance to the anticonvulsant effects of tiagabine following chronic (21 day) treatment.

Authors:  P D Suzdak
Journal:  Epilepsy Res       Date:  1994-12       Impact factor: 3.045

7.  The significance of extracellular GABA in the substantia nigra of the rat during seizures and anticonvulsant treatments.

Authors:  U Sayin; W Timmerman; B H Westerink
Journal:  Brain Res       Date:  1995-01-09       Impact factor: 3.252

8.  The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.

Authors:  A Fink-Jensen; P D Suzdak; M D Swedberg; M E Judge; L Hansen; P G Nielsen
Journal:  Eur J Pharmacol       Date:  1992-09-22       Impact factor: 4.432

Review 9.  Genetic absence epilepsy in rats from Strasbourg--a review.

Authors:  C Marescaux; M Vergnes; A Depaulis
Journal:  J Neural Transm Suppl       Date:  1992

10.  Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor.

Authors:  E B Nielsen; P D Suzdak; K E Andersen; L J Knutsen; U Sonnewald; C Braestrup
Journal:  Eur J Pharmacol       Date:  1991-04-24       Impact factor: 4.432

View more
  12 in total

1.  Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels.

Authors:  A Cleton; B A Altorf; R A Voskuyl; M Danhof
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 2.  Role of astrocytes in the maintenance and modulation of glutamatergic and GABAergic neurotransmission.

Authors:  Arne Schousboe
Journal:  Neurochem Res       Date:  2003-02       Impact factor: 3.996

Review 3.  Targeting inhibitory neurotransmission in tinnitus.

Authors:  Ben D Richardson; Thomas J Brozoski; Lynne L Ling; Donald M Caspary
Journal:  Brain Res       Date:  2012-02-14       Impact factor: 3.252

4.  Effects of γ-Aminobutyric acid transporter 1 inhibition by tiagabine on brain glutamate and γ-Aminobutyric acid metabolism in the anesthetized rat In vivo.

Authors:  Anant B Patel; Robin A de Graaf; Douglas L Rothman; Kevin L Behar
Journal:  J Neurosci Res       Date:  2015-02-06       Impact factor: 4.164

Review 5.  Pharmacological and functional characterization of astrocytic GABA transport: a short review.

Authors:  A Schousboe
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

6.  Neuropharmacological and neurobiological relevance of in vivo ¹H-MRS of GABA and glutamate for preclinical drug discovery in mental disorders.

Authors:  Conny F Waschkies; Andreas Bruns; Stephan Müller; Martin Kapps; Edilio Borroni; Markus von Kienlin; Markus Rudin; Basil Künnecke
Journal:  Neuropsychopharmacology       Date:  2014-04-03       Impact factor: 7.853

7.  Localization and Function of GABA Transporters GAT-1 and GAT-3 in the Basal Ganglia.

Authors:  Xiao-Tao Jin; Adriana Galvan; Thomas Wichmann; Yoland Smith
Journal:  Front Syst Neurosci       Date:  2011-07-28

8.  [11C]flumazenil binding is increased in a dose-dependent manner with tiagabine-induced elevations in GABA levels.

Authors:  W Gordon Frankle; Raymond Y Cho; N Scott Mason; Chi-Min Chen; Michael Himes; Christopher Walker; David A Lewis; Chester A Mathis; Rajesh Narendran
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

9.  Glutamate uptake triggers transporter-mediated GABA release from astrocytes.

Authors:  László Héja; Péter Barabás; Gabriella Nyitrai; Katalin A Kékesi; Bálint Lasztóczi; Orsolya Toke; Gábor Tárkányi; Karsten Madsen; Arne Schousboe; Arpád Dobolyi; Miklós Palkovits; Julianna Kardos
Journal:  PLoS One       Date:  2009-09-24       Impact factor: 3.240

10.  Impairment of GABA transporter GAT-1 terminates cortical recurrent network activity via enhanced phasic inhibition.

Authors:  Daniel S Razik; David J Hawellek; Bernd Antkowiak; Harald Hentschke
Journal:  Front Neural Circuits       Date:  2013-09-11       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.